Article
The effect of recombinant IgG antibodies against the leucine-33 form of the platelet beta3 integrin (HPA-1a) on platelet function.
Thrombosis and haemostasis - 1 Apr 2004
Joutsi-Korhonen Lotta, Preston Sandy, Smethurst Peter A, Ijsseldijk Martin, Schaffner-Reckinger Elisabeth, Armour Kathryn L, Watkins Nicholas A, Clark Michael R, de Groot Philip G, Farndale Richard W, Ouwehand Willem H, Williamson Lorna M
Abstract excerpt
Recombinant HPA-1a antibodies with Fc, mutated to remove destructive effector functions, have been developed as a potential therapy for fetomaternal alloimmune thrombocytopenia (FMAIT), via blockade of binding of human HPA-1a polyclonal antibodies to fetal HPA-1a1b platelets. We have assessed the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
